A Novel Basic Fibroblast Growth Factor Conjugate for Broad Therapeutic Application

Increases stability of bFGF and enhances bioactivity Minimum concentration of polymer required to stabilize bFGF Potentially any heparin binding protein can be conjugated to the polymer Increased lifetime of bFGF for potential in vivo applications

Potential products: topical treatment for wound healing or burn repair, as an injectable therapeutic for many different diseases, as cell culture additives for stem cell self renewal, and for the use as a reagent in research settings. Commercial applications: wound healing for chronic and acute wounds, wound healing after burn or burn repair, bone regrowth, cardioprotection, neuronal regeneration, and various kinds of tissue regenerationPersonal care products: bFGF proliferation of dermal fibroblast and keratinocytes, stimulation of hair growth, improvement of skin elasticity, wrinkle treatment, and collagen and elastin synthesis

Researchers in the laboratory of Dr. Heather Maynard at UCLA have developed a novel polymer conjugate of bFGF that remains stable under environmental stressors such as extended storage, heat, enzymes, low pH, and stirring. This technology embodies conjugation of a heparin-mimicking polymer to a therapeutic protein to increase stability and enhance bioactivity of the growth factor. The invention circumvents the issue of using heparin itself to encapsulate a protein, where the anti-coagulation properties of heparin may cause adverse effects in a patient. This innovation provides the first polymer conjugate of bFGF that enhances its bioactivity and stability under various denaturing conditions.

Inventor: MAYNARD, Heather D. | NGUYEN, Thi
Priority Number: WO2013082196A1
IPC Current: A61K004748 | A61K004730 | A61P001700
Assignee Applicant: The Regents of the University of California
Title: bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | CONJUGUÉS BFGF-POLYMÈRES, LEURS PROCÉDÉS DE FABRICATION ET LEURS APPLICATIONS
Usefulness: bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | CONJUGUÉS BFGF-POLYMÈRES, LEURS PROCÉDÉS DE FABRICATION ET LEURS APPLICATIONS
Summary: For treating or ameliorating a disorder (claimed); for treating wound healing for chronic and acute wounds, burn repair, bone regrowth, cardioprotection, neuronal protection and regeneration, and many different kinds of tissue regeneration.
Novelty: New heparin mimicking polymer comprising a reactive group that reacts with moiety in target protein causing covalent attachment of heparin mimicking polymer to target protein, useful for treating e.g. wound healing, burn repair

生物医学

医药成分

9925270

State Of Development

The invention has been tested in in vitro experiments, and stabilization and enhanced bioactivity of bFGF by the heparin mimicking polymer conjugate has been demonstrated. The polymer displays no cytotoxic activity and has no effect on receptor binding.

Background

Basic fibroblast growth factor (bFGF) is an important protein that has many commercial applications due in part to its involvement in numerous physiological functions including embryonic development, angiogenesis, tissue and bone regeneration, development/maintenance of the nervous system, stem cell renewal, and wound repair. The clinical use of bFGF has been hindered due to the instability and rapid degradation of the protein. Novel polymer conjugates of bFGF that retain biological activity and stability under stressors show promising use for a range of applications that include, but are not limited to, wound healing, burn repair, cardioprotection, bone regrowth, neuronal repair, stem cell self renewal, as well as use as a reagent in laboratory settings.

Related Materials

A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat Chem. (2013)
Nanoscale growth factor patterns by immobilization on a heparin-mimicking polymer. J Am Chem Soc. (2008)

Additional Technologies by these Inventors

• A Novel Glycopolymer to Enhance Protein Stability
• A Novel Method for Synthesizing Hydrogels
• PolyProtek: Platform for Delivering and Stabilizing Therapeutic Biologics, Vaccines, and Industrial Enzymes
• Update To Degradable Trehalose Glycopolymers
• Noncrushable/Nonabusable Pill Formulations
• Dual-Enzyme Responsive Peptides

Tech ID/UC Case

23217/2012-340-0

Related Cases

2012-340-0

美国

桌面版